{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:59:05Z","timestamp":1792789145841,"version":"4.5.0"},"reference-count":23,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Society of Finland","id":[{"id":"https:\/\/ror.org\/05pgg4z49","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Sigrid Jus?lius Foundation","id":[{"id":"https:\/\/ror.org\/00ckakm23","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody-drug conjugates (ADCs) based on Fc antigen-binding fragments (Fcabs) promise improved tumor penetration while retaining the FcRn-mediated long half-life. Building on prior spheroid studies, we directly compared a 50 kDa HER2-targeted Fcab-MMAE ADC with a matched 150 kDa control molecule (aDIG-Fcab-MMAE) consisting of the same HER2-targeting Fcab ADC equipped with additional non-targeting anti-digoxigenin (aDIG) Fab arms and trastuzumab Fab- and IgG-based ADCs (50 kDa T-Fab-MMAE and 150 kDa T-IgG-MMAE) using the same linker-payloads. Site-specific conjugation yielded high-purity DAR2 species with excellent serum stability. In vitro cytotoxicity assays revealed that Fcab-MMAE and aDIG-Fcab-MMAE exhibited lower potency compared to T-Fab-MMAE and T-IgG-MMAE, correlating with their approximately 10-fold lower binding affinity for HER2. A pharmacokinetic study in mice showed similar exposure for the Fcab-MMAE, its 150 kDa control, and a higher exposure for T-IgG-MMAE ADC, while the T-Fab-MMAE ADC cleared rapidly. In an NCI-N87 gastric cancer SCID mouse xenograft model, T-IgG-MMAE demonstrated superior efficacy, while Fcab-MMAE and aDIG-Fcab-MMAE showed similar efficacy despite their size difference, with T-Fab-MMAE showing lower efficacy. These data indicate that at similar exposure, reduced scaffold size alone may not improve in vivo efficacy.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00324","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:02:43Z","timestamp":1790352163000},"page":"1957-1962","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of an Fcab-Drug Conjugate with Other Antibody-Drug Conjugate Formats towards Exposure and Antitumor Activity"],"prefix":"10.1021","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-2759","authenticated-orcid":true,"given":"Sebastian","family":"Ja\u0308ger","sequence":"first","affiliation":[{"name":"Merck Healthcare KGaA , , ,","place":["Darmstadt, Germany, 64293"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1152-0933","authenticated-orcid":true,"given":"Birgit","family":"Piater","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA , , ,","place":["Darmstadt, Germany, 64293"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7377-8647","authenticated-orcid":true,"given":"Stephan","family":"Dickgiesser","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA , , ,","place":["Darmstadt, Germany, 64293"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Tonillo","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA , , ,","place":["Darmstadt, Germany, 64293"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hecht","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA , , ,","place":["Darmstadt, Germany, 64293"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Anderl","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA , , ,","place":["Darmstadt, Germany, 64293"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Minelli","sequence":"additional","affiliation":[{"name":"Research and Development, Merck Healthcare KGaA, RBM S.p.A.\u2014Istituto di Ricerche Biomediche \u2018A. Marxer,\u2019 an Affiliate of Merck KGaA , Via Ribes 1 ,","place":["Colleretto Giacosa, TO, Italy, 10010"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bertotti","sequence":"additional","affiliation":[{"name":"Research and Development, Merck Healthcare KGaA, RBM S.p.A.\u2014Istituto di Ricerche Biomediche \u2018A. Marxer,\u2019 an Affiliate of Merck KGaA , Via Ribes 1 ,","place":["Colleretto Giacosa, TO, Italy, 10010"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Rasche","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA , , ,","place":["Darmstadt, Germany, 64293"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Joensuu","sequence":"additional","affiliation":[{"name":"University of Helsinki , , ,","place":["Helsinki, Finland, 00290"]},{"name":"Helsinki University Hospital and University of Helsinki , ,","place":["Helsinki, Finland, 00290"]},{"name":"Helsinki University Hospital and University of Helsinki , , ,","place":["Helsinki, Finland, 00290"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Barok","sequence":"additional","affiliation":[{"name":"University of Helsinki , , ,","place":["Helsinki, Finland, 00290"]},{"name":"Helsinki University Hospital and University of Helsinki , ,","place":["Helsinki, Finland, 00290"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2285-4776","authenticated-orcid":true,"given":"Christian","family":"Schro\u0308ter","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA , , ,","place":["Darmstadt, Germany, 64293"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"1","key":"2026102103083392400_cit1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41698-025-01131-0","article-title":"The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer","volume":"9","author":"Lin","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"12","key":"2026102103083392400_cit2","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1016\/j.xphs.2021.08.002","article-title":"Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates","volume":"110","author":"Kaempffe","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"2026102103083392400_cit3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1021\/acs.bioconjchem.4c00124","article-title":"Welding PROxAb Shuttles: A Modular Approach for Generating Bispecific Antibodies via Site-Specific Protein-Protein Conjugation","volume":"35","author":"Lehmann","year":"2024","journal-title":"Bioconjug. Chem."},{"issue":"12","key":"2026102103083392400_cit4","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1021\/acs.bioconjchem.3c00363","article-title":"Generation and Characterization of Iduronidase-Cleavable ADCs","volume":"34","author":"Ja\u0308ger","year":"2023","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"2026102103083392400_cit5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"2026102103083392400_cit6","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1&gt;2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin."},{"issue":"8","key":"2026102103083392400_cit7","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1535-7163.mct-21-0193","article-title":"Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate","volume":"21","author":"Singh","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"2026102103083392400_cit8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/abt\/tbae005","article-title":"Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate","volume":"7","author":"Ma","year":"2024","journal-title":"Antib. Ther."},{"issue":"5\u22126","key":"2026102103083392400_cit9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1515\/hsz-2021-0321","article-title":"EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing","volume":"403","author":"Ja\u0308ger","year":"2022","journal-title":"Biol. Chem."},{"issue":"8","key":"2026102103083392400_cit10","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1021\/acs.bioconjchem.1c00240","article-title":"Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for Targeted Drug Delivery","volume":"32","author":"Ja\u0308ger","year":"2021","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"2026102103083392400_cit11","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1208\/s12248-017-0083-7","article-title":"Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates","volume":"19","author":"Tumey","year":"2017","journal-title":"AAPS J."},{"issue":"4","key":"2026102103083392400_cit12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1021\/bc5005747","article-title":"Effect of attachment site on stability of cleavable antibody drug conjugates","volume":"26","author":"Dorywalska","year":"2015","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"2026102103083392400_cit13","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.str.2017.04.014","article-title":"Fcab-HER2 Interaction: a Me\u0301nage a\u0300 Trois. Lessons from X-Ray and Solution Studies","volume":"25","author":"Lobner","year":"2017","journal-title":"Structure"},{"issue":"7","key":"2026102103083392400_cit14","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1080\/19420862.2019.1626652","article-title":"Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4","volume":"11","author":"Griffiths","year":"2019","journal-title":"MAbs"},{"issue":"10","key":"2026102103083392400_cit15","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1124\/dmd.119.087809","article-title":"Effect of Size on Solid Tumor Disposition of Protein Therapeutics","volume":"47","author":"Li","year":"2019","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"2026102103083392400_cit16","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/biot.201300387","article-title":"In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2\/neu binding sites","volume":"9","author":"Woisetschla\u0308ger","year":"2014","journal-title":"Biotechnol. J."},{"issue":"11","key":"2026102103083392400_cit17","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/mt.2015.127","article-title":"A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis","volume":"23","author":"Leung","year":"2015","journal-title":"Mol. Ther."},{"issue":"10","key":"2026102103083392400_cit18","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1124\/dmd.119.087023","article-title":"Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues","volume":"47","author":"Zhang","year":"2019","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"2026102103083392400_cit19","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/1535-7163.mct-06-0766","article-title":"Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance","volume":"6","author":"Barok","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"2026102103083392400_cit20","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1186\/bcr2868","article-title":"Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo","volume":"13","author":"Barok","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"6","key":"2026102103083392400_cit21","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.4049\/jimmunol.134.6.3798","article-title":"Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid)","volume":"134","author":"Dorshkind","year":"1985","journal-title":"J. Immunol."},{"issue":"10","key":"2026102103083392400_cit22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"22","key":"2026102103083392400_cit23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"Rubahamya","year":"2024","journal-title":"Sci. Adv."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00324","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/1957\/68660838\/bc6c00324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/1957\/68660838\/bc6c00324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:11:35Z","timestamp":1792570295000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/10\/1957\/5438993\/Comparison-of-an-Fcab-Drug-Conjugate-with-Other"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,10,21]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00324","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}